Industry partnering event with MSD
Enter your details below to access the audio and video recording of this event, and to receive updates about future virtual events.
If you’re already subscribed to IN-PART, please enter your details and you’ll be taken to the recordings.
In the first event of our latest Virtual Series, we spoke with Daniel Marshall, Director of Oncology Business Development at MSD. Daniel is currently the Director of Business Development for MSD, leading on oncology BD&L for Europe and the Middle East. He holds a PhD in Immunology from the National Institute for Medical Research and previously spent several years in Biotech venture capital investment. In this partnering event with MSD, we heard about their R&D priorities and the research they’re looking for from academia.
What’s covered in this event?
- 00:00 – Introduction to IN-PART
- 03:40 – Introduction to MSD
- 07:25 – Oncology at MSD
- 10:44 – What MSD are looking for
- 21:30 – Live Q&A
- 37:03 – Closing remarks
Format: Presentation followed by live Q&A (~40 minutes)
As part of our current Global Challenge uncovering next-generation immuno-oncology research, MSD have shared their interests through this webinar and in a one-page summary (company interests and priorities), with the view to identify new academic partners for collaboration and commercialisation partnerships.
About MSD: MSD are proud to deliver breakthrough innovations in oncology that are helping to extend the lives of patients with certain types of cancer including, blood, breast lung, gastrointestinal, head and neck, melanoma , prostate and renal cell carcinoma.
In the first event of our Virtual Series, running alongside our latest Global Challenges campaign, we’ll be speaking with external innovation and R&D leads from our immuno-oncology campaign partners to hear about the roadblocks they face, and the priority research they’re looking for from academia to support their product and R&D pipelines.
Some of the topics covered will include:
- The top priorities and technical challenges for each company
- What research solutions companies are actively searching for from academia
- The companies’ preferred approaches to partnering with academic research and expertise
Who should attend?
- Technology transfer, research commercialisation + industry engagement teams
- Academic researchers
- Industry R&D and open/external innovation teams
Run in partnership with:
ASTP are Europe’s premier association of knowledge transfer professionals whose work aims to improve the quality of impact that public research has on the economy and society. Learn more.
PraxisAuril are a world-leading professional association for
knowledge exchange practitioners, whose network includes 5000+ KE professionals. Learn more.
Labiotech.eu provide the biotech community with current and relevant information about the life sciences industry. They hope that professionals in the industry will collaborate more effectively so they can develop better products that benefit our society. Learn more.
BIA: The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. Learn more.
Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2023: ‘Industry partnering event with MSD’
What is IN-PART?
IN-PART develops digital solutions, curated by in-house STEM experts, that simplify the initial connection between decision-makers in academia and industry. Our goal is to help drive impact from research by matching innovation and expertise on a level playing field globally.
Connect, a digital partnering platform for university-industry collaboration.
An online matchmaking platform used by 250+ universities and research institutes to connect with industry teams in 6,000+ companies to commercialise academic innovations and expertise that are available and seeking collaboration.
Discover, a bespoke scouting service for open innovation.
A bespoke scouting platform used by innovation-driven companies to profile the global landscape of academia across an active network of 2,600+ institutes, either through ‘Industry Calls for Opportunities’ or ‘Request for Proposal’ campaigns that find and confirm potential solutions to specific R&D challenges or requirements.